Patents by Inventor Mark Matulenko
Mark Matulenko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240024338Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.Type: ApplicationFiled: June 14, 2023Publication date: January 25, 2024Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla E. Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao., Xiaochun Lou, Sean Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Valentino J. Stella, Eric A. Voight, Zhi Wang, Geoff G. Zhang
-
Publication number: 20230285378Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: ApplicationFiled: September 9, 2022Publication date: September 14, 2023Applicant: AbbVie Inc.Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Warren M. Kati, Tammie K. Jinkerson, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
-
Publication number: 20230106081Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.Type: ApplicationFiled: October 24, 2022Publication date: April 6, 2023Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla E. Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Valentino J. Stella, Eric A. Voight, Zhi Wang, Geoff G. Zhang
-
Publication number: 20220153765Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.Type: ApplicationFiled: July 16, 2021Publication date: May 19, 2022Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Valentino J. Stella, Eric A. Voight, Zhi Wang, Geoff G. Zhang
-
Publication number: 20200262852Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.Type: ApplicationFiled: May 4, 2020Publication date: August 20, 2020Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla E. Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Valentino J. Stella, Eric A. Voight, Zhi Wang, Geoff Zhang
-
Publication number: 20190375770Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.Type: ApplicationFiled: December 5, 2018Publication date: December 12, 2019Applicant: AbbVie Inc.Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla E. Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christiopher P. Miller, James Stambuli, Valentino J. Stella, Eric A. Voight, Zhi Wang, Geoff G. Zhang
-
Publication number: 20190015402Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: ApplicationFiled: July 23, 2018Publication date: January 17, 2019Applicant: AbbVie Inc.Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
-
Patent number: 10174061Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.Type: GrantFiled: September 26, 2017Date of Patent: January 8, 2019Assignee: ABBVIE INC.Inventors: Benoit Cardinal-David, Vincent S. Chan, Brian P. Enright, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Eric A. Voight, Zhi Wang, Geoff G. Zhang, Valentino J. Stella
-
Publication number: 20180334435Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.Type: ApplicationFiled: April 13, 2018Publication date: November 22, 2018Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
-
Patent number: 10039754Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: GrantFiled: February 13, 2017Date of Patent: August 7, 2018Assignee: AbbVie Inc.Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
-
Patent number: 10028937Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: GrantFiled: February 16, 2017Date of Patent: July 24, 2018Assignee: AbbVie Inc.Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
-
Patent number: 9969693Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.Type: GrantFiled: August 17, 2016Date of Patent: May 15, 2018Assignee: AbbVie Inc.Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
-
Publication number: 20180079762Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.Type: ApplicationFiled: September 26, 2017Publication date: March 22, 2018Applicant: AbbVie Inc.Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Eric A. Voight, Zhi Wang, Geoff G. Zhang, Valentino J. Stella
-
Patent number: 9783527Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.Type: GrantFiled: September 15, 2015Date of Patent: October 10, 2017Assignee: AbbVie Inc.Inventors: Jerome F. Daanen, David A. DeGoey, Jennifer M. Frost, John R. Koenig, Steve Latshaw, Mark Matulenko, Marc Scanio, Lei Shi, William H. Bunnelle
-
Publication number: 20170226062Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.Type: ApplicationFiled: August 17, 2016Publication date: August 10, 2017Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
-
Publication number: 20170157105Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: ApplicationFiled: February 16, 2017Publication date: June 8, 2017Applicant: AbbVie Inc.Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
-
Publication number: 20170157104Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: ApplicationFiled: February 13, 2017Publication date: June 8, 2017Applicant: AbbVie Inc.Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
-
Patent number: 9586978Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: GrantFiled: December 2, 2014Date of Patent: March 7, 2017Assignee: AbbVie Inc.Inventors: Mary E. Bellizzi, David A. Betebenner, Jean C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
-
Publication number: 20160362431Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.Type: ApplicationFiled: July 21, 2016Publication date: December 15, 2016Inventors: Benoit CARDINAL-DAVID, Vincent S. CHAN, Kassibla DEMPAH, Brian P. ENRIGHT, Rodger F. HENRY, Raimundo HO, Ye HUANG, Alexander D. HUTERS, Russell C. KLIX, Scott W. KRABBE, Philip R. KYM, Yanbin LAO, Xiaochun LOU, Sean E. MACKEY, Mark A. MATULENKO, Peter T. MAYER, Christopher P. MILLER, James STAMBULI, Eric A. VOIGHT, Zhi WANG, Geoff G. ZHANG, Valentino J. STELLA
-
Publication number: 20160355482Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.Type: ApplicationFiled: August 17, 2016Publication date: December 8, 2016Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield